| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Thrombectomy | 28 | 2026 | 105 | 4.920 |
Why?
|
| Embolization, Therapeutic | 21 | 2026 | 221 | 4.790 |
Why?
|
| Hematoma, Subdural, Chronic | 10 | 2025 | 13 | 3.580 |
Why?
|
| Meningeal Arteries | 12 | 2025 | 15 | 2.630 |
Why?
|
| Endovascular Procedures | 20 | 2026 | 704 | 2.320 |
Why?
|
| Stroke | 23 | 2026 | 1005 | 2.320 |
Why?
|
| Bone Screws | 8 | 2015 | 52 | 2.070 |
Why?
|
| Stents | 16 | 2026 | 741 | 1.820 |
Why?
|
| Atlanto-Axial Joint | 8 | 2015 | 21 | 1.760 |
Why?
|
| Intracranial Aneurysm | 9 | 2026 | 81 | 1.640 |
Why?
|
| Tinnitus | 2 | 2023 | 23 | 1.550 |
Why?
|
| Treatment Outcome | 64 | 2026 | 12325 | 1.380 |
Why?
|
| Neurosurgical Procedures | 6 | 2020 | 297 | 1.100 |
Why?
|
| Propensity Score | 8 | 2025 | 238 | 1.020 |
Why?
|
| Aged, 80 and over | 36 | 2026 | 6551 | 1.000 |
Why?
|
| Cranial Sinuses | 2 | 2023 | 13 | 0.980 |
Why?
|
| Cerebral Hemorrhage | 6 | 2025 | 149 | 0.970 |
Why?
|
| Aged | 54 | 2026 | 20004 | 0.910 |
Why?
|
| Magnesium Sulfate | 1 | 2024 | 51 | 0.880 |
Why?
|
| Retrospective Studies | 51 | 2026 | 16768 | 0.840 |
Why?
|
| Cervical Vertebrae | 2 | 2015 | 105 | 0.840 |
Why?
|
| Middle Aged | 57 | 2026 | 27329 | 0.830 |
Why?
|
| Neuroprotective Agents | 1 | 2024 | 155 | 0.800 |
Why?
|
| Drainage | 2 | 2016 | 249 | 0.800 |
Why?
|
| Constriction, Pathologic | 7 | 2023 | 224 | 0.780 |
Why?
|
| Cerebral Revascularization | 3 | 2023 | 22 | 0.780 |
Why?
|
| Infarction, Middle Cerebral Artery | 3 | 2026 | 33 | 0.700 |
Why?
|
| Hematoma, Subdural | 2 | 2023 | 25 | 0.690 |
Why?
|
| Spinal Fusion | 7 | 2018 | 110 | 0.670 |
Why?
|
| Brain Ischemia | 5 | 2023 | 253 | 0.670 |
Why?
|
| Humans | 97 | 2026 | 126084 | 0.670 |
Why?
|
| Craniotomy | 3 | 2016 | 100 | 0.610 |
Why?
|
| Cervical Atlas | 2 | 2016 | 6 | 0.600 |
Why?
|
| Male | 62 | 2026 | 62087 | 0.580 |
Why?
|
| Joint Instability | 3 | 2013 | 57 | 0.570 |
Why?
|
| Vertebral Artery | 3 | 2014 | 18 | 0.570 |
Why?
|
| Female | 63 | 2026 | 67913 | 0.570 |
Why?
|
| Angioplasty | 4 | 2024 | 65 | 0.550 |
Why?
|
| Tomography, X-Ray Computed | 9 | 2026 | 2026 | 0.500 |
Why?
|
| Arthrodesis | 2 | 2015 | 14 | 0.490 |
Why?
|
| Neurosurgery | 2 | 2014 | 73 | 0.490 |
Why?
|
| Tranexamic Acid | 1 | 2016 | 31 | 0.480 |
Why?
|
| Antifibrinolytic Agents | 1 | 2016 | 47 | 0.470 |
Why?
|
| Anesthesia, General | 3 | 2025 | 121 | 0.470 |
Why?
|
| Registries | 11 | 2026 | 1477 | 0.470 |
Why?
|
| Anticoagulants | 3 | 2023 | 564 | 0.450 |
Why?
|
| Orthopedic Procedures | 1 | 2015 | 75 | 0.430 |
Why?
|
| Angioplasty, Balloon | 2 | 2025 | 129 | 0.420 |
Why?
|
| Spinal Injuries | 1 | 2013 | 30 | 0.410 |
Why?
|
| Aneurysm, Ruptured | 2 | 2015 | 31 | 0.410 |
Why?
|
| Carotid Artery Diseases | 1 | 2014 | 133 | 0.400 |
Why?
|
| Arachnoid | 2 | 2023 | 9 | 0.400 |
Why?
|
| Spinal Cord | 2 | 2021 | 244 | 0.390 |
Why?
|
| Betacoronavirus | 3 | 2020 | 282 | 0.380 |
Why?
|
| Prostheses and Implants | 1 | 2014 | 144 | 0.380 |
Why?
|
| Carotid Stenosis | 2 | 2025 | 102 | 0.380 |
Why?
|
| Heparin | 1 | 2013 | 202 | 0.370 |
Why?
|
| Fibrinolytic Agents | 2 | 2025 | 195 | 0.370 |
Why?
|
| Aneurysm, False | 1 | 2012 | 72 | 0.350 |
Why?
|
| Arteries | 1 | 2012 | 198 | 0.350 |
Why?
|
| Thrombolytic Therapy | 2 | 2025 | 202 | 0.350 |
Why?
|
| Venous Thromboembolism | 1 | 2013 | 166 | 0.340 |
Why?
|
| Coronavirus Infections | 3 | 2020 | 359 | 0.340 |
Why?
|
| Vascular Diseases | 1 | 2012 | 149 | 0.340 |
Why?
|
| Pneumonia, Viral | 3 | 2020 | 372 | 0.340 |
Why?
|
| Congenital Abnormalities | 1 | 2014 | 300 | 0.330 |
Why?
|
| Surgeons | 1 | 2015 | 278 | 0.330 |
Why?
|
| Evidence-Based Medicine | 1 | 2014 | 606 | 0.320 |
Why?
|
| Intracranial Arteriovenous Malformations | 2 | 2023 | 33 | 0.320 |
Why?
|
| Middle Cerebral Artery | 3 | 2021 | 115 | 0.320 |
Why?
|
| Adult | 20 | 2026 | 30253 | 0.300 |
Why?
|
| Cerebral Angiography | 3 | 2026 | 104 | 0.300 |
Why?
|
| Vertebrobasilar Insufficiency | 2 | 2026 | 8 | 0.300 |
Why?
|
| Subarachnoid Hemorrhage | 2 | 2022 | 63 | 0.280 |
Why?
|
| Delivery of Health Care | 1 | 2014 | 664 | 0.280 |
Why?
|
| Radial Artery | 2 | 2025 | 31 | 0.270 |
Why?
|
| Angiography | 2 | 2020 | 188 | 0.260 |
Why?
|
| Blood Vessel Prosthesis | 3 | 2020 | 442 | 0.240 |
Why?
|
| Decompressive Craniectomy | 1 | 2025 | 10 | 0.230 |
Why?
|
| Recovery of Function | 2 | 2024 | 429 | 0.220 |
Why?
|
| Femoral Artery | 1 | 2025 | 141 | 0.220 |
Why?
|
| Neuroimaging | 2 | 2025 | 357 | 0.220 |
Why?
|
| Radiosurgery | 2 | 2016 | 105 | 0.220 |
Why?
|
| Tissue Plasminogen Activator | 1 | 2025 | 112 | 0.220 |
Why?
|
| Reperfusion | 2 | 2020 | 25 | 0.210 |
Why?
|
| Carotid Artery, Internal | 3 | 2024 | 56 | 0.200 |
Why?
|
| Skull | 3 | 2023 | 147 | 0.200 |
Why?
|
| Blood Coagulation Disorders | 1 | 2024 | 105 | 0.200 |
Why?
|
| Moyamoya Disease | 1 | 2023 | 40 | 0.190 |
Why?
|
| Vasospasm, Intracranial | 1 | 2022 | 18 | 0.190 |
Why?
|
| Balloon Embolectomy | 2 | 2018 | 2 | 0.190 |
Why?
|
| Fetal Stem Cells | 2 | 2012 | 5 | 0.190 |
Why?
|
| Drug-Eluting Stents | 1 | 2023 | 62 | 0.190 |
Why?
|
| Combined Modality Therapy | 3 | 2025 | 1216 | 0.180 |
Why?
|
| Intracranial Arteriosclerosis | 1 | 2021 | 6 | 0.180 |
Why?
|
| Arterial Occlusive Diseases | 1 | 2022 | 99 | 0.180 |
Why?
|
| Urinary Retention | 1 | 2021 | 18 | 0.180 |
Why?
|
| Patient Selection | 1 | 2025 | 702 | 0.180 |
Why?
|
| Maternal-Fetal Exchange | 2 | 2012 | 80 | 0.180 |
Why?
|
| Central Nervous System Vascular Malformations | 1 | 2021 | 18 | 0.180 |
Why?
|
| Radiology, Interventional | 1 | 2021 | 35 | 0.180 |
Why?
|
| Ischemic Attack, Transient | 1 | 2021 | 59 | 0.170 |
Why?
|
| Pregnancy Complications, Cardiovascular | 2 | 2012 | 107 | 0.170 |
Why?
|
| Temporal Arteries | 1 | 2021 | 31 | 0.170 |
Why?
|
| Pandemics | 4 | 2021 | 1132 | 0.170 |
Why?
|
| New York City | 4 | 2021 | 63 | 0.170 |
Why?
|
| Brain Infarction | 1 | 2020 | 28 | 0.170 |
Why?
|
| Hemangioma, Cavernous, Central Nervous System | 1 | 2020 | 20 | 0.170 |
Why?
|
| Time-to-Treatment | 4 | 2024 | 196 | 0.170 |
Why?
|
| Pons | 1 | 2020 | 33 | 0.170 |
Why?
|
| Product Surveillance, Postmarketing | 1 | 2020 | 26 | 0.160 |
Why?
|
| Comprehensive Health Care | 1 | 2020 | 13 | 0.160 |
Why?
|
| Brain Neoplasms | 2 | 2022 | 1224 | 0.160 |
Why?
|
| Skull Base | 2 | 2020 | 47 | 0.160 |
Why?
|
| Infectious Disease Transmission, Patient-to-Professional | 1 | 2020 | 39 | 0.160 |
Why?
|
| Empirical Research | 1 | 2019 | 9 | 0.160 |
Why?
|
| Spinal Cord Diseases | 1 | 2020 | 29 | 0.160 |
Why?
|
| Arteriovenous Malformations | 1 | 2020 | 47 | 0.160 |
Why?
|
| Arteriovenous Fistula | 1 | 2020 | 55 | 0.150 |
Why?
|
| Neoplasms | 1 | 2014 | 2848 | 0.150 |
Why?
|
| Catheters | 3 | 2024 | 81 | 0.150 |
Why?
|
| Glioblastoma | 1 | 2022 | 332 | 0.150 |
Why?
|
| Cerebrovascular Disorders | 1 | 2019 | 111 | 0.150 |
Why?
|
| Hyperglycemia | 1 | 2020 | 225 | 0.140 |
Why?
|
| Postoperative Complications | 2 | 2025 | 2967 | 0.140 |
Why?
|
| Delivery of Health Care, Integrated | 1 | 2020 | 142 | 0.140 |
Why?
|
| Biomechanical Phenomena | 2 | 2018 | 252 | 0.140 |
Why?
|
| Spinal Diseases | 1 | 2018 | 43 | 0.140 |
Why?
|
| Glioma | 1 | 2022 | 478 | 0.140 |
Why?
|
| Quality Indicators, Health Care | 1 | 2020 | 220 | 0.140 |
Why?
|
| Lumbar Vertebrae | 1 | 2018 | 103 | 0.130 |
Why?
|
| Time Factors | 5 | 2024 | 6015 | 0.130 |
Why?
|
| Confidence Intervals | 2 | 2014 | 255 | 0.130 |
Why?
|
| Epidermal Cyst | 1 | 2016 | 17 | 0.130 |
Why?
|
| Neuroendoscopy | 1 | 2016 | 32 | 0.130 |
Why?
|
| Nervous System Neoplasms | 1 | 2016 | 7 | 0.120 |
Why?
|
| Blood Glucose | 1 | 2020 | 1087 | 0.120 |
Why?
|
| Dermoid Cyst | 1 | 2016 | 34 | 0.120 |
Why?
|
| Epilepsy | 2 | 2016 | 843 | 0.120 |
Why?
|
| Finite Element Analysis | 1 | 2016 | 33 | 0.120 |
Why?
|
| Recurrence | 3 | 2026 | 1399 | 0.120 |
Why?
|
| Carotid-Cavernous Sinus Fistula | 1 | 2015 | 11 | 0.120 |
Why?
|
| Clinical Trials as Topic | 1 | 2020 | 1096 | 0.110 |
Why?
|
| Health Personnel | 1 | 2020 | 531 | 0.110 |
Why?
|
| Printing, Three-Dimensional | 1 | 2016 | 83 | 0.110 |
Why?
|
| Models, Anatomic | 1 | 2016 | 103 | 0.110 |
Why?
|
| Vascular Access Devices | 1 | 2015 | 35 | 0.110 |
Why?
|
| Case-Control Studies | 1 | 2022 | 3303 | 0.110 |
Why?
|
| Tuberous Sclerosis | 1 | 2016 | 135 | 0.110 |
Why?
|
| Vascular Patency | 1 | 2015 | 177 | 0.110 |
Why?
|
| Quality Improvement | 1 | 2020 | 677 | 0.110 |
Why?
|
| Young Adult | 5 | 2016 | 9616 | 0.110 |
Why?
|
| Thrombosis | 1 | 2018 | 501 | 0.100 |
Why?
|
| Patients | 1 | 2015 | 122 | 0.100 |
Why?
|
| Treatment Failure | 2 | 2025 | 331 | 0.100 |
Why?
|
| Computer-Assisted Instruction | 1 | 2014 | 56 | 0.100 |
Why?
|
| Intention to Treat Analysis | 2 | 2024 | 60 | 0.100 |
Why?
|
| Cadaver | 1 | 2013 | 115 | 0.100 |
Why?
|
| Hydrocephalus | 1 | 2016 | 280 | 0.100 |
Why?
|
| Physician's Role | 1 | 2015 | 160 | 0.100 |
Why?
|
| Data Collection | 1 | 2015 | 367 | 0.100 |
Why?
|
| Osteoarthritis, Spine | 1 | 2012 | 2 | 0.100 |
Why?
|
| Sex Distribution | 1 | 2013 | 307 | 0.100 |
Why?
|
| Age Distribution | 1 | 2013 | 416 | 0.090 |
Why?
|
| Alberta | 2 | 2023 | 61 | 0.090 |
Why?
|
| Braces | 1 | 2012 | 12 | 0.090 |
Why?
|
| Radiography | 1 | 2014 | 749 | 0.090 |
Why?
|
| Thoracic Vertebrae | 1 | 2012 | 66 | 0.090 |
Why?
|
| Arachnoid Cysts | 1 | 2012 | 9 | 0.090 |
Why?
|
| Risk Factors | 5 | 2025 | 10394 | 0.090 |
Why?
|
| Pain | 1 | 2015 | 428 | 0.090 |
Why?
|
| Coronary Artery Disease | 1 | 2018 | 827 | 0.090 |
Why?
|
| Terminology as Topic | 1 | 2013 | 222 | 0.090 |
Why?
|
| Pilot Projects | 1 | 2016 | 1386 | 0.090 |
Why?
|
| Imaging, Three-Dimensional | 1 | 2014 | 379 | 0.090 |
Why?
|
| Preoperative Care | 1 | 2014 | 350 | 0.090 |
Why?
|
| Cohort Studies | 3 | 2026 | 4920 | 0.090 |
Why?
|
| Hospitalization | 2 | 2020 | 1838 | 0.090 |
Why?
|
| Hypothalamic Diseases | 1 | 2012 | 38 | 0.090 |
Why?
|
| Risk | 1 | 2013 | 726 | 0.090 |
Why?
|
| Hamartoma | 1 | 2012 | 49 | 0.090 |
Why?
|
| Wounds and Injuries | 1 | 2015 | 377 | 0.090 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2016 | 481 | 0.090 |
Why?
|
| Stem Cell Transplantation | 1 | 2012 | 226 | 0.080 |
Why?
|
| Animals | 5 | 2024 | 33119 | 0.080 |
Why?
|
| Severity of Illness Index | 2 | 2020 | 2936 | 0.080 |
Why?
|
| Vagus Nerve Stimulation | 1 | 2011 | 59 | 0.080 |
Why?
|
| Abnormalities, Multiple | 1 | 2016 | 964 | 0.080 |
Why?
|
| Myocardial Ischemia | 1 | 2012 | 294 | 0.080 |
Why?
|
| Attitude of Health Personnel | 1 | 2015 | 693 | 0.080 |
Why?
|
| Education, Medical, Graduate | 1 | 2014 | 532 | 0.080 |
Why?
|
| Prospective Studies | 3 | 2025 | 6093 | 0.070 |
Why?
|
| Adolescent | 4 | 2016 | 19935 | 0.070 |
Why?
|
| Cell Movement | 1 | 2011 | 847 | 0.070 |
Why?
|
| United States | 3 | 2023 | 11201 | 0.070 |
Why?
|
| Magnetic Resonance Imaging | 3 | 2026 | 3680 | 0.070 |
Why?
|
| Follow-Up Studies | 3 | 2026 | 5050 | 0.060 |
Why?
|
| Myocardium | 1 | 2011 | 843 | 0.060 |
Why?
|
| Prevalence | 1 | 2013 | 2578 | 0.060 |
Why?
|
| Basilar Artery | 1 | 2026 | 18 | 0.060 |
Why?
|
| Child | 6 | 2016 | 25060 | 0.060 |
Why?
|
| Mechanical Thrombolysis | 1 | 2025 | 10 | 0.060 |
Why?
|
| Infarction, Anterior Cerebral Artery | 1 | 2024 | 2 | 0.060 |
Why?
|
| Myocardial Infarction | 1 | 2011 | 910 | 0.060 |
Why?
|
| Administration, Intravenous | 1 | 2025 | 165 | 0.050 |
Why?
|
| Cell Differentiation | 1 | 2011 | 1849 | 0.050 |
Why?
|
| Diffusion Magnetic Resonance Imaging | 1 | 2025 | 148 | 0.050 |
Why?
|
| Computed Tomography Angiography | 1 | 2026 | 203 | 0.050 |
Why?
|
| Incidence | 2 | 2023 | 3213 | 0.050 |
Why?
|
| Disability Evaluation | 1 | 2025 | 188 | 0.050 |
Why?
|
| Internship and Residency | 1 | 2014 | 1194 | 0.050 |
Why?
|
| Polymethyl Methacrylate | 1 | 2023 | 13 | 0.050 |
Why?
|
| Cerebral Infarction | 1 | 2023 | 46 | 0.050 |
Why?
|
| Anterior Cerebral Artery | 1 | 2022 | 6 | 0.050 |
Why?
|
| Intracranial Hemorrhages | 1 | 2022 | 69 | 0.050 |
Why?
|
| Dilatation | 1 | 2022 | 69 | 0.050 |
Why?
|
| Cytoreduction Surgical Procedures | 1 | 2022 | 49 | 0.050 |
Why?
|
| Retreatment | 1 | 2022 | 86 | 0.050 |
Why?
|
| Paraparesis | 1 | 2021 | 5 | 0.050 |
Why?
|
| Walruses | 1 | 2021 | 1 | 0.050 |
Why?
|
| Platelet Aggregation Inhibitors | 1 | 2024 | 266 | 0.050 |
Why?
|
| Disease Models, Animal | 1 | 2012 | 4409 | 0.050 |
Why?
|
| Carotid Artery, Common | 1 | 2021 | 59 | 0.040 |
Why?
|
| Vasodilator Agents | 1 | 2022 | 190 | 0.040 |
Why?
|
| Biomarkers | 2 | 2020 | 3138 | 0.040 |
Why?
|
| Green Fluorescent Proteins | 2 | 2012 | 376 | 0.040 |
Why?
|
| Cranial Fossa, Posterior | 1 | 2020 | 18 | 0.040 |
Why?
|
| Constipation | 1 | 2021 | 120 | 0.040 |
Why?
|
| Cerebral Small Vessel Diseases | 1 | 2020 | 9 | 0.040 |
Why?
|
| Blood Sedimentation | 1 | 2020 | 26 | 0.040 |
Why?
|
| Fibrin Fibrinogen Degradation Products | 1 | 2020 | 38 | 0.040 |
Why?
|
| Troponin | 1 | 2020 | 55 | 0.040 |
Why?
|
| Causality | 1 | 2020 | 89 | 0.040 |
Why?
|
| Thrombophilia | 1 | 2020 | 39 | 0.040 |
Why?
|
| Prone Position | 1 | 2020 | 30 | 0.040 |
Why?
|
| Operating Rooms | 1 | 2020 | 75 | 0.040 |
Why?
|
| Critical Pathways | 1 | 2020 | 69 | 0.040 |
Why?
|
| Personal Protective Equipment | 1 | 2020 | 52 | 0.040 |
Why?
|
| Patient Positioning | 1 | 2020 | 48 | 0.040 |
Why?
|
| Workflow | 1 | 2020 | 133 | 0.040 |
Why?
|
| Monitoring, Intraoperative | 1 | 2020 | 124 | 0.040 |
Why?
|
| Patient Admission | 1 | 2020 | 170 | 0.040 |
Why?
|
| Aphasia | 1 | 2018 | 14 | 0.040 |
Why?
|
| Age Factors | 1 | 2025 | 2771 | 0.040 |
Why?
|
| Feasibility Studies | 1 | 2021 | 790 | 0.040 |
Why?
|
| Endoscopy | 1 | 2020 | 280 | 0.040 |
Why?
|
| Ultrasonography | 1 | 2023 | 935 | 0.040 |
Why?
|
| Range of Motion, Articular | 1 | 2018 | 79 | 0.030 |
Why?
|
| Brain | 2 | 2022 | 3032 | 0.030 |
Why?
|
| Patient Care Team | 1 | 2020 | 548 | 0.030 |
Why?
|
| Disease Progression | 1 | 2022 | 2099 | 0.030 |
Why?
|
| Survival Rate | 1 | 2020 | 2060 | 0.030 |
Why?
|
| Comorbidity | 1 | 2020 | 1537 | 0.030 |
Why?
|
| Patient Care Planning | 1 | 2016 | 122 | 0.030 |
Why?
|
| Graft Occlusion, Vascular | 1 | 2015 | 76 | 0.030 |
Why?
|
| Cerebral Arteries | 1 | 2015 | 80 | 0.030 |
Why?
|
| Prognosis | 1 | 2023 | 4709 | 0.030 |
Why?
|
| Diagnosis, Differential | 1 | 2018 | 1845 | 0.030 |
Why?
|
| Zygapophyseal Joint | 1 | 2012 | 4 | 0.020 |
Why?
|
| Neck Pain | 1 | 2012 | 16 | 0.020 |
Why?
|
| CDX2 Transcription Factor | 1 | 2011 | 11 | 0.020 |
Why?
|
| Fluorescent Antibody Technique | 1 | 2012 | 412 | 0.020 |
Why?
|
| Data Interpretation, Statistical | 1 | 2012 | 216 | 0.020 |
Why?
|
| Mice, Inbred Strains | 1 | 2011 | 291 | 0.020 |
Why?
|
| Headache | 1 | 2012 | 104 | 0.020 |
Why?
|
| Infant | 2 | 2016 | 12761 | 0.020 |
Why?
|
| Calcinosis | 1 | 2012 | 182 | 0.020 |
Why?
|
| In Vitro Techniques | 1 | 2011 | 821 | 0.020 |
Why?
|
| Child, Preschool | 2 | 2016 | 14329 | 0.020 |
Why?
|
| Muscle, Smooth, Vascular | 1 | 2011 | 223 | 0.020 |
Why?
|
| Vision Disorders | 1 | 2012 | 188 | 0.020 |
Why?
|
| Flow Cytometry | 1 | 2012 | 758 | 0.020 |
Why?
|
| Models, Animal | 1 | 2011 | 452 | 0.020 |
Why?
|
| Reoperation | 1 | 2012 | 788 | 0.020 |
Why?
|
| Pregnancy | 2 | 2012 | 7404 | 0.020 |
Why?
|
| Endothelium, Vascular | 1 | 2011 | 460 | 0.020 |
Why?
|
| Homeodomain Proteins | 1 | 2011 | 538 | 0.020 |
Why?
|
| Biopsy | 1 | 2012 | 1234 | 0.020 |
Why?
|
| Anticonvulsants | 1 | 2011 | 376 | 0.020 |
Why?
|
| Longitudinal Studies | 1 | 2011 | 1421 | 0.020 |
Why?
|
| Myocytes, Cardiac | 1 | 2011 | 609 | 0.020 |
Why?
|
| Electroencephalography | 1 | 2011 | 820 | 0.020 |
Why?
|
| Mice, Transgenic | 1 | 2011 | 2311 | 0.020 |
Why?
|
| Cells, Cultured | 1 | 2011 | 2902 | 0.020 |
Why?
|
| Mice | 2 | 2012 | 17584 | 0.010 |
Why?
|
| Infant, Newborn | 1 | 2016 | 8357 | 0.010 |
Why?
|
| Mice, Inbred C57BL | 1 | 2012 | 4496 | 0.010 |
Why?
|
| Transcription Factors | 1 | 2011 | 2341 | 0.010 |
Why?
|